---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-24-000007"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:16:04.191297+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MoonLake FY 2023 net loss $44.1M; cash $511M; sonelokimab Phase 3 prep advances

## Summary
- Cash, cash equivalents and short-term marketable debt securities $511.0M at Dec 31, 2023, up from $496M at Sep 30, 2023.
- Net loss for FY 2023 $44.1M, improved from $64.5M in FY 2022.
- R&D expenses $31.8M in FY 2023, down from $42.0M in FY 2022.
- Completed positive Phase 2 data for sonelokimab in HS and PsA; FDA/EMA feedback supports Phase 3 VELA program in HS.
- Raised $85M gross proceeds from at-the-market offerings; cash runway expected to end of 2026.

## SEC filing metadata
- accession: 0001821586-24-000007
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158624000007/0001821586-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158624000007/mnlk-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-24-000007
- JSON: https://secwatch.observer/filing/0001821586-24-000007.json
- Plain text: https://secwatch.observer/filing/0001821586-24-000007.txt

## Key facts
- Earnings Releases
  MoonLake Immunotherapeutics reported the quarter and fiscal year ended December 31, 2023 results: net income $44.1 million.
  - Period: the quarter and fiscal year ended December 31, 2023
  - Net income: $44.1 million
  - Result: reported results
  source text: MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000182158624000007/0001821586-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.